IRIS
Caffo, Orazio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.341
AS - Asia 1.133
EU - Europa 977
SA - Sud America 157
AF - Africa 31
OC - Oceania 3
Totale 3.642
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.293
IT - Italia 435
SG - Singapore 411
CN - Cina 194
VN - Vietnam 186
DE - Germania 132
BR - Brasile 116
FI - Finlandia 95
RU - Federazione Russa 95
BD - Bangladesh 78
HK - Hong Kong 75
KR - Corea 64
FR - Francia 41
GB - Regno Unito 41
IN - India 28
CA - Canada 24
ID - Indonesia 23
LV - Lettonia 23
NL - Olanda 21
SE - Svezia 20
IQ - Iraq 14
MX - Messico 14
AR - Argentina 13
PL - Polonia 13
AT - Austria 12
IE - Irlanda 12
SA - Arabia Saudita 10
UA - Ucraina 10
ZA - Sudafrica 10
JP - Giappone 9
TR - Turchia 8
EC - Ecuador 7
VE - Venezuela 6
CZ - Repubblica Ceca 5
JO - Giordania 5
PK - Pakistan 5
CO - Colombia 4
ES - Italia 4
NP - Nepal 4
PH - Filippine 4
CL - Cile 3
EG - Egitto 3
GT - Guatemala 3
KE - Kenya 3
MA - Marocco 3
MY - Malesia 3
PE - Perù 3
UY - Uruguay 3
AL - Albania 2
BG - Bulgaria 2
DZ - Algeria 2
HN - Honduras 2
HU - Ungheria 2
LT - Lituania 2
MK - Macedonia 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
PY - Paraguay 2
QA - Qatar 2
TH - Thailandia 2
UZ - Uzbekistan 2
AO - Angola 1
AU - Australia 1
AZ - Azerbaigian 1
BB - Barbados 1
BE - Belgio 1
CG - Congo 1
CH - Svizzera 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
IL - Israele 1
KG - Kirghizistan 1
LB - Libano 1
LS - Lesotho 1
LU - Lussemburgo 1
LY - Libia 1
MT - Malta 1
OM - Oman 1
PA - Panama 1
PR - Porto Rico 1
PT - Portogallo 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
TW - Taiwan 1
ZM - Zambia 1
ZW - Zimbabwe 1
Totale 3.642
Salva come PNG Salva come JPEG
Città #
Singapore 291
Ashburn 179
San Jose 160
Trento 140
Munich 103
Helsinki 74
Santa Clara 69
Hong Kong 68
Council Bluffs 64
Seoul 62
Los Angeles 60
Dallas 56
Ho Chi Minh City 54
Milan 51
New York 44
Fairfield 41
Hanoi 37
Chandler 36
Columbus 35
Moscow 31
Beijing 26
Rome 26
Riga 23
Chicago 22
Houston 22
Lauterbourg 21
The Dalles 21
Da Nang 17
Verona 17
Jacksonville 16
Orem 16
Wilmington 16
Ogden 15
Seattle 15
Buffalo 13
Princeton 13
Jakarta 12
Hefei 11
Nuremberg 11
St Louis 11
São Paulo 11
Boardman 10
Cambridge 10
Shenzhen 10
Toronto 10
Warsaw 10
Chennai 9
Mattarello 9
Miano 9
Salt Lake City 9
San Mateo 9
Woodbridge 9
Ann Arbor 8
Atlanta 8
London 8
North Bergen 8
Tokyo 8
Dublin 7
Frankfurt am Main 7
Lappeenranta 7
Vienna 7
Baghdad 6
Cincinnati 6
Denver 6
Jyväskylä 6
Modena 6
Paris 6
Redondo Beach 6
Vicenza 6
Amman 5
Curitiba 5
Daiano 5
Falkenstein 5
Florence 5
Haiphong 5
Istanbul 5
Johannesburg 5
Manchester 5
Mexico City 5
Phoenix 5
Boston 4
Can Tho 4
Como 4
Dammam 4
Detroit 4
Hải Dương 4
Jersey City 4
San Francisco 4
Shanghai 4
Waterbury 4
Wuxi 4
Bari 3
Brno 3
Bắc Giang 3
Bắc Ninh 3
Caracas 3
Dearborn 3
Dhaka 3
Edison 3
Guangzhou 3
Totale 2.356
Salva come PNG Salva come JPEG
Nome #
A model-based framework to identify optimal administration protocols for immunotherapies in castration-resistance prostate cancer 257
Sterile inflammation via TRPM8 RNA-dependent TLR3-NF-kB/IRF3 activation promotes antitumor immunity in prostate cancer 168
Novel Treatment Strategies for Hormone Receptor (HR)-Positive, HER2-Negative Metastatic Breast Cancer 167
Oral selective estrogen receptor degraders (SERDs): The new emperors in breast cancer clinical practice? 157
TRPM8 levels determine tumor vulnerability to channel agonists. 142
Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment 139
Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation 134
Integrating extracellular vesicle and circulating cell-free DNA analysis on a single plasma aliquot improves the detection of HER2 positivity in breast cancer patients 132
Optimal Sequencing of New Drugs in Metastatic Castration-Resistant Prostate Cancer: Dream or Reality? 130
Immune-Related Adverse Events Due to Cancer Immunotherapy: Immune Mechanisms and Clinical Manifestations 125
Complete pathological response to pembrolizumab in pretreated pancreatic acinar cell carcinoma 118
1730P Electronic medical record (EMR)-assisted phone follow-up (PFU) for breast cancer survivors (CS) during COVID-19 pandemic: An Italian single institution experience 112
Electronic Medical Record-Assisted Telephone Follow-Up of Breast Cancer Survivors During the COVID-19 Pandemic: A Single Institution Experience 111
Impact of KRAS mutations on clinical outcomes of patients with advanced non-squamous non-small cell lung cancer receiving anti PD1/PDL1 therapy 106
Plasma microRNA Signature as Companion Diagnostic for Abiraterone Acetate Treatment in Metastatic Castration-Resistant Prostate Cancer: A Pilot Study 89
Risk of cardiovascular toxicity with combination of immune-checkpoint inhibitors and angiogenesis inhibitors: a meta-analysis 86
Tissue microarrays in oncology. 69
Myositis and myasthenia during nivolumab administration for advanced lung cancer: a case report and review of the literature 67
Role of circulating tumor DNA in the detection of sensitizing and resistance to epidermal growth factor receptor mutations in metastatic lung adenocarcinoma 62
Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer 61
Osimertinib in the Treatment of Epidermal Growth Factor Receptor-Mutant Early and Locally Advanced Stages of Non-Small-Cell Lung Cancer: Current Evidence and Future Perspectives 55
Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study 54
Rheumatic immune-and nonimmune-related adverse events in phase 3 clinical trials assessing PD-(L)1 checkpoint inhibitors for lung cancer: A systematic review and meta-analysis 48
Defining the Position of [177Lu]Lu-PSMA Radioligand Therapy in the Treatment Landscape of Metastatic Castration-Resistant Prostate Cancer: A Meta-analysis of Clinical Trials 47
Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort study 39
Prostate Cancer Diagnosis and Treatment in Elderly Patients: A Cross-Sectional Survey Exploring Practice Patterns and Preferences of Uro-Oncologists in Northeast Italy 39
Radioligand Therapies (RLTs) and Healthcare System Readiness: From the Experience in GEP-NET, a Retrospective Analysis on DRG and Mobility to Improve the Accessibility to the Future RLT in Italy 34
Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1 < 50%: results from an Italian observational study 32
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study 32
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors 30
Germline Findings From Tumor-Only Comprehensive Genomic Profiling in the RATIONAL Study: A Missed Opportunity? 29
Development and Validation of Prognostic Model for Metastatic Castration-Resistant Prostate Cancer Patients Treated With First-Line Abiraterone or Enzalutamide 28
The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma 28
Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study 28
Survival, treatment duration and costs of patients with prostate cancer treated with triptorelin in Italy: a study of administrative databases 27
Clinical, Diagnostic and Therapeutic Framework of mHSPC and nmCRPC: A Multidisciplinary Consensus Project of the Italian Society for Uro-Oncology (SIUrO) 25
Association of G8 screening tool with prognosis and survival in patients with non-small cell lung cancer: A retrospective analysis from a single institution 25
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab 24
Clinical Outcomes and Prognostic Factors in Patients With Penile Carcinoma: A Sub-Analysis From Meet-URO 23 (I-RARE) Registry Study 24
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1) 24
Prognostic Role of Inflammatory and Nutritional Biomarkers in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors Alone or in Combination with Chemotherapy as First-Line 24
Concomitant Administration of VEGFR Tyrosine Kinase and Proton Pump Inhibitors May Impair Clinical Outcome of Patients With Metastatic Renal Cancer 24
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care 23
Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study 23
Efficacy and Safety of Pembrolizumab plus Axitinib combination for Metastatic Renal Cell Carcinoma in a Real-World Scenario: Data From the Prospective ProPAXI Study 23
A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study) 23
Evaluating Treatment Efficacy in Metastatic Hormone-sensitive Prostate Cancer Patients with Visceral Disease: A Systematic Review and Network Meta-analysis 23
Prognostic factors of long-term response to androgen receptor signaling inhibitors used as first-line treatment for mCRPC 22
Meet-URO Score Validation in Real-world Patients with Metastatic Renal Cell Carcinoma Receiving First-line Pembrolizumab Plus axitinib: A Subanalysis of the Prospective ProPAXI Study 22
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? 22
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience 21
Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 21
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study 21
Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies 21
Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study 20
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis 20
Testing BRCA 1-2 Mutations in Metastatic Prostate Cancer: Results of a Survey of the Italian Association of Medical Oncology 19
The Expanding Role of Next-generation Imaging in Prostate Cancer Management: A Cross-sectional Survey Exploring the Clinical Practice of Uro-oncologists in North-Eastern Italy; On Behalf of GUONE (Gruppo Uro-Oncologico del Nord-Est) 19
Organized prostate cancer screening program: a proposal from the Italian Society of Urology (SIU) 19
BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications 18
nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives 18
Matching BRCA and prostate cancer in a public health system: Report of the Italian Society for Uro-Oncology (SIUrO) consensus project 17
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022 17
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC) 17
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1) 17
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021 15
Darolutamide Maintenance in Patients With Metastatic Castration- Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16) 15
First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series 14
Prostate cancer: Screening and early detection 14
Prognostic Value of p21WAF1 and p53 Expression in Breast Carcinoma: An Immunohistochemical Study in 261 Patients with Long-Term Follow-Up 14
Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer 12
Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer 12
Is There Room for Liposomal Irinotecan in Biliary Tract Cancer? A Meta-analysis of Randomised Trials 11
Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer 11
Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. 10
Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone 9
A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study 9
Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer 8
Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome? 8
Pain and quality of life after surgery for breast cancer 7
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study 6
A Remote Monitoring System to Optimize the Home Management of Oral Anticancer Therapies (ONCO-TreC): Prospective Training-Validation Trial 6
Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review 4
Cardiovascular toxicities of systemic treatments of prostate cancer 4
A report of progressive multifocal leukoencephalopathy during adjuvant abemaciclib for breast cancer 4
Modified 3-week schedule of gemcitabine plus cisplatin for non-small cell lung cancer treatment 4
Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer 4
Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer. 4
Adherence to Oral Treatments in Older Patients with Advanced Prostate Cancer, the ADHERE Study: A Prospective Trial of the Meet-URO Network 4
The role of mean corpuscular volume and red cell distribution width in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: the MARECAP retrospective study 3
Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial 3
International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer. 3
What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. 3
Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis. 3
BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR-positive non small cell lung cancer patients: Results from a multicenter Italian observational study. 3
Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone 3
Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study 3
Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients 3
Radiochemotherapy for non small cell lung cancer 3
Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer 3
Totale 3.860
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.764
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.764
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211 0 0 0 0 0 0 0 0 0 0 0 1
2021/202299 0 1 0 12 12 0 13 25 6 2 9 19
2022/202380 10 13 0 11 5 11 1 3 7 7 8 4
2023/202482 4 2 4 2 3 8 4 10 5 13 9 18
2024/2025814 13 11 43 108 49 88 86 58 94 104 41 119
2025/20262.705 104 47 141 204 137 87 237 74 724 515 142 293
Totale 3.905